title: Should we be using cimetidine to premedicate patients receiving docetaxel or paclitaxel?
authors.forename: Thomas
authors.initials: T
authors.lastname: Clouse
authors.forename: John P
authors.initials: JP
authors.lastname: Geisler
authors.forename: Kelly J
authors.initials: KJ
authors.lastname: Manahan
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Gudenkauf
authors.forename: Georgiann
authors.initials: G
authors.lastname: Linnemeier
authors.forename: Michael C
authors.initials: MC
authors.lastname: Wiemann
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000494:pharmacology*; D016190:Carboplatin / Q000008:administration & dosage / Q000493:pharmacokinetics; D002927:Cimetidine / Q000008:administration & dosage / Q000494:pharmacology*; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D000077143:Docetaxel; D004357:Drug Synergism; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000201:enzymology; D017239:Paclitaxel / Q000008:administration & dosage / Q000493:pharmacokinetics; D043823:Taxoids / Q000008:administration & dosage / Q000493:pharmacokinetics
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002927:Cimetidine; D003577:Cytochrome P-450 Enzyme System; D016190:Carboplatin; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D017239:Paclitaxel; D002945:Cisplatin